General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novartis Corporation(MODEST) RESEARCH/RESEARCH GRANTS: Novartis(NONE), Novo Nordisk Inc.(SIGNIFICANT), Amgen Inc.(SIGNIFICANT), Kaneka(SIGNIFICANT) OTHER FINANCIAL BENEFIT: G3 Therapeutics(SIGNIFICANT)

View Full Disclosure